Product Description
to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00947895)
Mechanisms of Action: MCR Agonist
Novel Mechanism: No
Modality: N/A
Route of Administration: Intramuscular,Intravenous,Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University of California, San Diego
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Multiple Sclerosis|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| PREVENT-WS | N/A |
Unknown status |
Infantile Spasms|Spasms, Infantile |
2018-12-01 |
|
| NCT01062568 | P3 |
Completed |
Other |
2014-07-01 |
|
| NCT00989781 | N/A |
Completed |
Polycystic Ovary Syndrome |
2013-09-01 |
|
| RECLAIM | P3 |
Terminated |
Multiple Sclerosis |
2011-01-01 |